Karen J. Wilson's most recent trade in Elicio Therapeutics Inc. was a trade of 7,900 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 19, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Elicio Therapeutics Inc. | Karen J. Wilson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 7,900 | 7,900 | - | - | Stock Option (Right to Buy) | |
| LAVA Therapeutics NV | Karen J. Wilson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 33,390 | 33,390 | - | - | Common Shares (Right to Buy) | |
| Elicio Therapeutics Inc. | Karen J. Wilson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 4,100 | 4,100 | - | - | Stock Option (Right to Buy) | |
| Vaxart Inc | Karen J. Wilson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 15,097 | 15,097 | - | - | Stock Option (right to buy) | |
| Vaxart Inc | Karen J. Wilson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Aug 2020 | 65,700 | 65,700 | - | - | Stock Option (right to buy) |